Stock fact sheet · data as of
Apimeds Pharmaceuticals US, Inc (APUS): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is APUS undervalued?
At 4.39 (close of 16 Oct 2026), APUS has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -35.63 and it pays no dividend), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.
The nightly engine files APUS under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for APUS
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 2.09 | -52% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Apimeds Pharmaceuticals US, Inc scores only 1 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.6/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -3.7%, ROE -3.9%, ROA -3.7% - with debt at 0.05 times equity and negative free cash flow.
Apimeds Pharmaceuticals US, Inc pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 1 / 9 | ROIC | -3.7% |
|---|---|---|---|
| GLS Moat | 1.6 / 10 | ROE | -3.9% |
| Debt / equity | 0.05 | ROA | -3.7% |
| Free-cash-flow yield | -210.1% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 23: No options
No options are listed on Apimeds Pharmaceuticals US, Inc in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 23) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 109k shares a day on a market cap of $7M, with a beta of 0.15 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 13 / 25 | 0% margin of safety | |
| Health | 2 / 20 | Piotroski 1/9 | |
| Moat | 2 / 15 | moat 1.6/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 109k shares/day, $7M cap, beta 0.15 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for APUS in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Apimeds Pharmaceuticals US, Inc by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| IMRN Immuron Limited | 1.03 | - | - | 30No options | $7M |
| FBLG FibroBiologics, Inc. Common Stock | 1.00 | 0.7260 | -38% | 14No options | $7M |
| ACXP Acurx Pharmaceuticals, Inc. | 1.17 | 5.07 | +77% | 38No options | $7M |
| CUBT Curative Biotechnology, Inc. | 0.9500 | - | - | 24No options | $6M |
| AIM AIM ImmunoTech Inc. | 0.1703 | - | - | 31No options | $7M |
| SKYE Skye Bioscience, Inc. | 1.57 | 0.7856 | -100% | 3Weak | $7M |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | 0.4782 | 3.09 | +85% | 36Weak | $6M |
| ZEOX Zeo ScientifiX, Inc. | 0.9000 | - | - | 31No options | $7M |
| ENVB Enveric Biosciences, Inc. | 1.39 | 12.40 | +89% | 37No options | $6M |
| NCNA NuCana plc | 1.02 | 14.66 | +93% | 33No options | $6M |
| AIMD Ainos, Inc. | 0.9600 | - | - | 19No options | $7M |
| ALZN Alzamend Neuro Inc | 1.28 | - | - | 23No options | $6M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about APUS
Is APUS undervalued right now?
The GLS models could not value APUS (the company lost money over the last twelve months, EPS -35.63 and it pays no dividend), so there is no fair value or margin of safety to compare the price of 4.39 against.
What is the Wheel Score of APUS and what does it mean?
APUS has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for APUS?
None of the nine GLS models produced a positive value for APUS (the company lost money over the last twelve months, EPS -35.63 and it pays no dividend), so there is no GLS fair value tonight.
When does Apimeds Pharmaceuticals US, Inc report earnings next?
No upcoming earnings date is recorded for APUS in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does APUS have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on APUS, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.